Navigation Links
Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center. [Ed : Her2/neu is a protein often present / surexpressed in breast cancer] Their study, published in the online journal, Breast Cancer Research, on Nov. 29, 2004, showed that the vaccine protected 86 percent of experimental mice against HER2/neu-associated breast cancer, even though the tumors were implanted directly into mice.

“This is an exciting strategy that seems to elicit a complete immunologic response against HER2/neu,?says the study’s lead author, Lawrence Lachman, Ph.D., a professor in the Department of Experimental Therapeutics. “Now that we have gone as far as we can in animal studies, I hope this agent might be tested clinically both to treat HER2/neu breast tumors, and to prevent them from spreading.?Up to one-third of human breast cancers are associated with over-expression of the HER2/neu cell surface receptor protein, which continuously “tells?the cancer cell to grow, this producing an aggressive disease that is difficult to stop. The drug Herceptin treats this kind of breast cancer by “plugging?these receptors with a monoclonal antibody, but this treatment “produces only a passive and transitory immune reaction,?Lachman said. “This vaccine, however, like many that treat microbial infections, appears to create a memory in the immune system that produces a lasting protective response.?The vaccine used in this study is a “viral-vectored?approach, in which a naturally occurring virus is re-engineered to be propagation defective but still able to function as a delivery system for proteins from the cancer cells that are to be targeted by the animal’s immune system. The basis for this new va
'"/>

Source:M.D. Anderson Cancer Center


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. NIAID Initiates Trial of Experimental Avian Flu Vaccine
4. Study Models Impact Of Anthrax Vaccine
5. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
6. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
7. EuroVacc 02 HIV Vaccine Trial Begins
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... of dinosaur unearthed in Mexico is giving scientists fresh insights ... an international research team led by scientists from the Utah ... To date, the dinosaur record from Mexico has been sparse, ... Natural History, Utahs designated natural history museum. The new ...
... HANOVER, N.H. Dartmouth College researchers and colleagues from ... the beginnings of complex life, i.e. vertebrates, to microRNA. ... regulate gene expression, are behind the origin of early ... to understanding the evolutionary origin of our own lineage, ...
... goal of Raphael Kopan, Ph.D., professor of molecular biology ... The moss plant (Physcomitrella patens) studied in the ... Professor and chair of the WUSTL biology department on ... Heres how. The gene presenilin in mammals ...
Cached Biology News:New dinosaur from Mexico offers insights into ancient life on West America 2New dinosaur from Mexico offers insights into ancient life on West America 3New dinosaur from Mexico offers insights into ancient life on West America 4New dinosaur from Mexico offers insights into ancient life on West America 5New dinosaur from Mexico offers insights into ancient life on West America 6Dartmouth researchers find the root of the evolutionary emergence of vertebrates 2Moss protein plays role in Alzheimer's disease 2Moss protein plays role in Alzheimer's disease 3Moss protein plays role in Alzheimer's disease 4
(Date:3/31/2015)... Orlando, Florida (PRWEB) March 31, 2015 ... announced the official relocation of their U.S. facilities and ... more than 25 years of experience, Cryos’ relocation is ... presence. , The move to Orlando was completed during ... with an official opening taking place on April 6. ...
(Date:3/30/2015)... 2015  Multiple new research abstracts suggest walnuts may ... factors. From their impact on colon cancer and certain ... both gut health and vascular health, the research findings ... understanding of walnuts, inner workings. Running March 28 through ... annual meeting attracts an international audience of over 14,000 ...
(Date:3/30/2015)... Md. , March 30, 2015 CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... Food and Drug Administration (CFDA) has approved the Company,s ... in ovarian clear cell carcinoma (OCCC) patients for its ...
(Date:3/30/2015)... March 30, 2015 Immunocore ... drugs to treat cancer, viral infections and autoimmune ... John Bell , the Regius Professor of ... Office for the Strategic Coordination of Health Research, ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) ...
Breaking Biology Technology:Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... Aug. 19 /PRNewswire-Asia/ -- ... ... var shortURL = ""; ... so we need to grab the first one. for (var r in data.results) { first_result = ...
... LONDON, Aug. 19 Silence Therapeutics plc (AIM: SLN), ... note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has ... obtain an exclusive worldwide license to develop and commercialise ... Silence,s AtuRNAi technology. Quark is currently conducting ...
... THE WOODLANDS, Texas, Aug. 19 US Oncology, ... today that in less than two decades it has ... cancer therapies approved by the US Food and Drug ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 3US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 4
... Vibratome Roto-Shake Genie is an all-in-one ... It performs five different mixing motions: ... rotating/rolling, as well as a combination ... precision-engineered moving portion of the Vibraotme ...
... Roches RTS AviTag E. coli Biotinylation Kit, Plasmid ... and 500 E. coli expression kits. (Cat. No. ... 461). This kit provides vectors for the easy ... sequence. The expressed protein can be enzymatically mono-biotinylated ...
... Mouse monoclonal [1320] to RFC1 Immunogen ... human Replication Factor C expressed in E. coli. ... and S. cerevisiae. Not yet tested in other ... RFC1 Background Information Replication factor ...
...
Biology Products: